Skip to content

Cagrilintide

Preclinical only

Cagrilintide is a long-acting amylin analog — a different mechanism than GLP-1 agonists. It works via amylin receptors in the brain to reduce appetite and slow gastric emptying. In Phase 3 trials; not yet FDA-approved as standalone. Being studied in combination with semaglutide (CagriSema) for enhanced efficacy. Not medical advice; consult a provider.

How Cagrilintide works

Cagrilintide targets amylin receptors, offering a different mechanism than GLP-1 or GIP agonists. May complement rather than replace GLP-1 therapy. Evidence is evolving; use only with provider guidance.

Researched benefits

  • •Amylin pathway — distinct from GLP-1 agonists
  • •May complement GLP-1 therapy rather than replace it
  • •Phase 3 trials ongoing
  • •CagriSema (with semaglutide) under study for enhanced efficacy

What it is studied for

  • •Weight and metabolic research where amylin pathway is of interest
  • •Combination approaches with GLP-1 therapy in clinical trials

Reported side effects and cautions

  • •Limited long-term data; not yet FDA-approved standalone
  • •Similar GI considerations to other appetite-modifying agents
  • •Use only in research or provider-directed protocols

Evidence rating: Preclinical only

Evidence comes from laboratory or animal research. Human safety and effectiveness have not been established.

Other peptides

BPC157TB500 (Thymosin B4 Acetate)Semaglutide (Ozempic / Wegovy)Tirzepatide (GLP-1/GIP dual agonist)Retatrutide + Cagrilintide (combination)GHK-CU

See every peptide in the library →

Educational information only. This page is not medical advice, not a prescription, and not a recommendation to use Cagrilintide. Dosing figures describe what appears in published research and provider protocols — they are not instructions. Several compounds covered here are prescription medicines. Talk to a licensed healthcare provider before acting on anything you read.